U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H15N5
Molecular Weight 193.2493
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALVAMELINE

SMILES

CCn1nc(C2=CCCN(C)C2)nn1

InChI

InChIKey=RNMOMKCRCIRYCZ-UHFFFAOYSA-N
InChI=1S/C9H15N5/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8/h5H,3-4,6-7H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C9H15N5
Molecular Weight 193.2493
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: DOI: 10.1016/0024-3205(95)93724-S
Curator's Comment:: http://adisinsight.springer.com/drugs/800001965 | https://www.ncbi.nlm.nih.gov/pubmed/10668706

Alvameline is a partial agonist of the M1 mAChR that also displays M2/M3 antagonist effects. It readily crosses the blood-brain barrier. It has an effect profile that makes it of interest to test its ability to counteract bladder overactivity in humans. Behaviorally, alvameline has been shown to significantly improve Morris water maze (MWM) performance in both young and ageimpaired rats. It failed to improve cognition in patients with mild to moderate Alzheimer's disease.

Originator

Sources: DOI: 10.1016/0024-3205(95)93724-S

Approval Year

PubMed

PubMed

TitleDatePubMed
Lu 25-109, a combined m1 agonist and m2 antagonist, modulates regulated processing of the amyloid precursor protein of Alzheimer's disease.
1998
A bridging study of LU 25-109 in patients with probable Alzheimer's disease.
1998
In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro.
1998 Jun
Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group.
2000 Jan 25
Actions of the new antimuscarinic compound Lu 25-109 on isolated human and pig detrusor.
2002
Patents

Sample Use Guides

25, 50, or 100 mg three times a day
Route of Administration: Oral
Radioligand binding experiments demonstrated a small difference in affinity for Alvameline in the parotid gland compared with the bladder, the pKi values being 6.2 versus 6.5 (n=4).
Substance Class Chemical
Created
by admin
on Sat Jun 26 04:00:17 UTC 2021
Edited
by admin
on Sat Jun 26 04:00:17 UTC 2021
Record UNII
4XFD7B36M6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALVAMELINE
INN   WHO-DD  
INN  
Official Name English
ALVAMELINE [INN]
Common Name English
ALVAMELINE [WHO-DD]
Common Name English
LU 25-109
Common Name English
5-(2-ETHYL-2H-TETRAZOL-5-YL)-1-METHYL-1,2,3,6-TETRAHYDROPYRIDINE
Systematic Name English
PYRIDINE, 3-(2-ETHYL-2H-TETRAZOL-5-YL)-1,2,5,6-TETRAHYDRO-1-METHYL-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C47796
Created by admin on Sat Jun 26 04:00:18 UTC 2021 , Edited by admin on Sat Jun 26 04:00:18 UTC 2021
Code System Code Type Description
INN
7742
Created by admin on Sat Jun 26 04:00:18 UTC 2021 , Edited by admin on Sat Jun 26 04:00:18 UTC 2021
PRIMARY
ChEMBL
CHEMBL131428
Created by admin on Sat Jun 26 04:00:18 UTC 2021 , Edited by admin on Sat Jun 26 04:00:18 UTC 2021
PRIMARY
PUBCHEM
178030
Created by admin on Sat Jun 26 04:00:18 UTC 2021 , Edited by admin on Sat Jun 26 04:00:18 UTC 2021
PRIMARY
NCI_THESAURUS
C77842
Created by admin on Sat Jun 26 04:00:18 UTC 2021 , Edited by admin on Sat Jun 26 04:00:18 UTC 2021
PRIMARY
EVMPD
SUB00420MIG
Created by admin on Sat Jun 26 04:00:18 UTC 2021 , Edited by admin on Sat Jun 26 04:00:18 UTC 2021
PRIMARY
WIKIPEDIA
ALVAMELINE
Created by admin on Sat Jun 26 04:00:18 UTC 2021 , Edited by admin on Sat Jun 26 04:00:18 UTC 2021
PRIMARY
CAS
120241-31-8
Created by admin on Sat Jun 26 04:00:18 UTC 2021 , Edited by admin on Sat Jun 26 04:00:18 UTC 2021
PRIMARY
FDA UNII
4XFD7B36M6
Created by admin on Sat Jun 26 04:00:18 UTC 2021 , Edited by admin on Sat Jun 26 04:00:18 UTC 2021
PRIMARY
EPA CompTox
120241-31-8
Created by admin on Sat Jun 26 04:00:18 UTC 2021 , Edited by admin on Sat Jun 26 04:00:18 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
AMOUNT EXCRETED
USP
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
TARGET -> AGONIST
Related Record Type Details
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
PLASMA
METABOLITE -> PARENT
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
MAJOR
FECAL; PLASMA
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY